Boston – November 06, 2026 -- Servier will present nine abstracts, including five oral presentations, at the 31st Society for Neuro-Oncology (SNO) Annual Meeting, held November 12-15 in Philadelphia. The package covers both of its glioma therapies: VORANIGO (vorasidenib) in IDH-mutant glioma and OJEMDA (tovorafenib) in BRAF-altered pediatric low-grade glioma (pLGG).
Four-year FIREFLY-1 data to cover retreatment after progression in pLGG
One oral presentation will deliver updated results from the four-year follow-up of the Phase 2 FIREFLY-1 study of OJEMDA in relapsed or refractory BRAF-altered pLGG. The analysis includes data on post-treatment observation and on retreatment with OJEMDA after disease progression.
Servier's source material cites an estimated US incidence of 1,100 and a European incidence of 700 children per year eligible for front-line systemic therapy. BRAF alterations account for more than 50% of pLGG cases worldwide. Before OJEMDA, no approved treatments existed for pLGG driven by BRAF fusions.
Phase 3 INDIGO follow-up reaches a median of 41.6 months in Grade 2 disease
Two oral presentations will draw on the Phase 3 INDIGO trial. The first reports extended follow-up, with a median overall duration of 41.6 months, in patients with Grade 2 IDH-mutant glioma randomized to VORANIGO. It includes subgroup analyses by histological subtype. Servier states the results show sustained, long-term clinical benefit regardless of prognostic factors.
A second analysis found that long-term VORANIGO treatment generally led to a sustained decrease in seizure activity and delayed worsening of quality of life.
Real-world cohorts of 499 and 80 patients extend VORANIGO data beyond INDIGO
Two oral presentations will cover retrospective observational analyses of VORANIGO use outside the trial setting.
- In 499 patients with Grade 2 IDH-mutant glioma, time-to-next-intervention (TTNI) analyses showed short-term real-world effectiveness. The highest rate was among frontline VORANIGO users.
- In a cohort of 80 patients with Grade 3 IDH-mutant glioma, the analysis showed emerging evidence of effectiveness.
Islam Hassan, Servier's Global Head of Development, Neuro-Oncology, said the expanded clinical and real-world evidence for both drugs is intended to deepen understanding of these diseases and support further treatment advances for adults and children.